Alnylam Pharmaceuticals Inc’s recently made public that its CSO & EVP, Head of Research Fitzgerald Kevin Joseph unloaded Company’s shares for reported $5.97 million on Aug 12 ’24. In the deal valued at $270.99 per share,22,025 shares were sold. As a result of this transaction, Fitzgerald Kevin Joseph now holds 12,881 shares worth roughly $3.46 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Fitzgerald Kevin Joseph bought 22,025 shares, generating $5,936,178 in total proceeds.
Before that, Ausiello Dennis A sold 20,250 shares. Alnylam Pharmaceuticals Inc shares valued at $5,305,586 were divested by the Director at a price of $262.00 per share. As a result of the transaction, Ausiello Dennis A now holds 136 shares, worth roughly $36480.64.
Goldman upgraded its Alnylam Pharmaceuticals Inc [ALNY] rating to a Buy from a a Neutral in a research note published on August 16, 2024; the price target was increased to $370 from $198. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in mid February from “a Buy” to “a Neutral”. Wolfe Research began covering ALNY with “Peer perform” recommendation on February 15, 2024. Wells Fargo started covering the stock on December 08, 2023. It rated ALNY as “an Equal weight”.
Price Performance Review of ALNY
On Friday, Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] saw its stock jump 2.11% to $268.24. Over the last five days, the stock has lost -0.47%. Alnylam Pharmaceuticals Inc shares have risen nearly 40.14% since the year began. Nevertheless, the stocks have risen 48.91% over the past one year. While a 52-week high of $274.93 was reached on 08/02/24, a 52-week low of $141.98 was recorded on 04/25/24. SMA at 50 days reached $230.22, while 200 days put it at $179.80.
Levels Of Support And Resistance For ALNY Stock
The 24-hour chart illustrates a support level at 262.54, which if violated will result in even more drops to 256.84. On the upside, there is a resistance level at 273.32. A further resistance level may holdings at 278.40. The Relative Strength Index (RSI) on the 14-day chart is 64.67, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.38, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 15.66%. Stochastics%K at 75.85% indicates the stock is a holding.
How much short interest is there in Alnylam Pharmaceuticals Inc?
A steep rise in short interest was recorded in Alnylam Pharmaceuticals Inc stocks on 2024-07-31, growing by 0.65 million shares to a total of 4.33 million shares. Yahoo Finance data shows the prior-month short interest on 2024-06-28 was 3.68 million shares. There was a rise of 15.0%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 08, 2023 when Wells Fargo began covering the stock and recommended ‘”an Equal weight”‘ rating.
